Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled trial of HDM SLIT-tablet in children with house dust mite allergic rhinitis/rhinoconjunctivitis
2019-000560-22Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Jun 2019
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of House dust mite allergen extract in house dust mite allergic rhinitis and allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by ALK-Abelló. Primary endpoint: Primary efficacy endpoint during the efficacy assessment period. Started Jun 2019; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
house dust mite allergic rhinitisallergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2019-000560-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000560-22.